The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move aimed at accelerating the delivery of innovative cancer treatments, Pfizer Canada announced that BRAFTOVI (encorafenib) will be funded under Ontario's Facilitated Access to Systemic Treatment (FAST) program. This marks the first Pfizer therapy to receive such priority access, specifically targeting patients with metastatic colorectal cancer harboring the BRAF V600E mutation. According to reports, the initiative seeks to reduce long wait times for oncology drugs in Canada through strategic collaboration between the industry and the provincial government.
This development comes as major pharmaceutical firms intensify their focus on oncology, with Pfizer reporting a 31% revenue increase in its oncology division during Q1 2024. In comparison to peers, Eli Lilly’s Erbitux, often used in combination for colorectal treatments, generated $147 million in the latest quarter per market data. The inclusion of BRAFTOVI in the FAST program strengthens Pfizer’s competitive positioning in the Canadian market, which serves as a strategic hub for specialized medicine growth.
Sign in to access this content
Sign InMarket-wise, PFE shares stood at $28.45 (close May 22, 2026) as investors assess the cumulative impact of regional regulatory wins on global margins. Looking ahead, traders are monitoring the FOMC Minutes scheduled for May 20, 2026, for insights into interest rate trajectories that influence R&D financing in the healthcare sector. While the stock remains near key support levels, the expansion of rapid access programs provides a steady qualitative catalyst for the company's oncology pipeline.